Navigation Links
Researchers unfold the mechanisms underlying blood disorders
Date:7/24/2012

A Finnish research team together with researchers from New York, USA, has uncovered a protein structure that regulates cell signalling and the formation of blood cells. The team's results, published in Nature Structural & Molecular Biology, the most prestigious journal in the field, shed light on the mechanisms at play in haematological disorders and provide new opportunities for the design of disease-specific treatment. The work was carried out with funding from the Academy of Finland, the Cancer Society of Finland, National Institutes of Health and the Sigrid Juslius Foundation.

Blood cell formation and activity is regulated by cytokines, small cell-signalling protein molecules, through a signal pathway mediated by Janus kinases (JAKs), a family of enzymes. Previous studies have shown that mutations in JAKs can cause severe haematological disorders as well as immunological diseases. These mutations are concentrated in the pseudokinase domain.

Leading laboratories and pharmaceutical companies around the world have long aimed at defining the structure of the pseudokinase domain of JAKs, as it has been found to be a veritable hotspot for pathogenic mutations causing haematological disorders. Led by Professor Olli Silvennoinen, the Finnish research team has now successfully determined the three-dimensional atomic-level structure of both the normal and the pathogenic pseudokinase domain.

Novel therapeutics

Professor Silvennoinen's team is the first to describe the structure of the pseudokinase domain of JAKs, laying bare the domain's enzymatic mechanisms at the atomic level. The team also managed to determine the structural change, caused by the JAK2 V617F mutation, which gives rise to common myeloproliferative diseases (MPDs), such as polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). PV and ET are blood disorders characterised by an overproduction of red blood cells or platelets, whereas MF is a disorder that causes scar tissue to accumulate in the bone marrow. The team's research results can be put to good use in developing new, targeted therapeutics for these disorders.

The study now published in Nature Structural & Molecular Biology builds on the long-standing expertise of Professor Silvennoinen's team in Janus kinases. In the early 1990s, while working in the US, Silvennoinen successfully cloned the JAK2 gene and demonstrated its activity in the signalling pathways of erythropoietin and interferon. In Finland, the Silvennoinen's work focused on the pseudokinase domain, determining and characterising its regulatory function.


'/>"/>
Contact: Professor Olli Silvennoinen
olli.silvennoinen@uta.fi
358-503-595-740
Academy of Finland
Source:Eurekalert

Related medicine news :

1. New lipid screening guidelines for children overly aggressive, UCSF researchers say
2. BUSM researchers identify genetic markers for testosterone, estrogen level regulation
3. UGA researchers develop rapid diagnostic test for pathogens, contaminants
4. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
5. Researchers link Kawasaki Disease in childhood with increased risk of adult heart disease
6. Researchers to use novel metabolomics technology for COPD
7. Researchers hit back at early bodycheck theory
8. Cleveland Clinic researchers discover molecule that may prevent atherosclerosis
9. Researchers developing new multiple sclerosis drug that can be taken orally
10. UMass Amherst researchers unravel secrets of parasites replication
11. U-M researchers identify new genetic cause for chronic kidney disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Angeles, California (PRWEB) , ... March 22, 2017 , ... ... signed British boxing champ Ashley Theophane as a new Brand Ambassador. Theophane, who trained ... British light welterweight title in 2011. He has racked up an impressive number of ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... announced that its digital marketing solutions have enabled Children’s Hospital of The King’s ... months. , Recognizing the value of a digital marketing approach, the 206-bed ...
(Date:3/22/2017)... ... March 22, 2017 , ... The ... research collaboration to translate advances in basic neuroscience at the BMRI labs into ... collaboration seeks to improve movement, vision, and cognition impaired by stroke, traumatic brain ...
(Date:3/22/2017)... ... 2017 , ... The Vanderbeck Agency, a Long Island firm providing insurance, financial ... on a combined charity effort with the Great Neck Breast Cancer Coalition to provide ... Great Neck Breast Cancer Coalition has worked to support breast cancer patients in the ...
(Date:3/22/2017)... ... ... Chris Humphrey Insurance Agency, a North Carolina firm offering asset protection services and ... initiating a charity event to raise support for five year old Dillyn, a young ... Friday evening in September 2014. At the time, Dillyn was only four years old, ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 22, 2017 Under the ... pharmaceutical packaging market size increased year by year ... 2017 to 2021, the market size will maintain ... expected to outnumber RMB140 billion in 2021, thanks ... rapid development of biological agents and supporting policies. ...
(Date:3/22/2017)...  ImaginAb Inc. today announced the appointment of Martyn Coombs ... , chairman of ImaginAb, said "At ImaginAb we have exciting science ... relevant to our business, particularly in commercializing and making step changes ... we can realize our potential." ... Mr. Coombs is a recognized industry leader in nuclear ...
(Date:3/22/2017)... 2017  CANTEL MEDICAL CORP. (NYSE: CMD ) ... CEO, will be presenting at the 16 th Annual ... Hotel in New York . The formal ... p.m. ET. In addition, management will be available for separate ... audio webcast will be available via the investor relations page ...
Breaking Medicine Technology: